最近，双特异性抗体（BsAb）正在改变癌症治疗的格局，并显着改善了复发或难治性癌症患者的治疗结果。随着越来越多的双特异性抗体进入临床实践，出现了特定的毒性，并且已经描述了肾脏副作用。然而，目前缺乏系统分析抗癌双特异性抗体受体肾毒性的研究。在这篇综述中，我们展示了 BsAbs 接受者肾损伤的病因、机制、其他危险因素和治疗选择，以便更全面地了解 BsAbs 治疗后的肾毒性。值得注意的是，由于每个受试者的临床试验数据有限，我们主要总结 T 细胞接合 BsAb 受体中发生肾毒性的相关病因、机制和危险因素。与非 T 细胞 BsAb 相关的肾毒性可能与针对两种特定抗原的相关单克隆抗体的不良肾毒性有关。本文的目的是为肾病学家和肿瘤学家提供理论知识，以便为接受 BsAb 治疗的接受者提供更好的医疗管理，特别是 T 细胞参与 BsAb 治疗。© 2024 Wen 和 Xu。

Recently, bispecific antibodies (BsAbs) are evolving the landscape of cancer treatment and have significantly improved the outcomes of relapsed or refractory cancer patients. As increasing BsAbs entered clinical practice, specific toxicities have emerged, and renal side-effects have been described. However, there are a lack of studies analyzing the nephrotoxicity in the anti-cancer BsAbs recipients systematically. In this review, we demonstrate the etiologies, mechanisms, other risk factors and treatment options of kidney injury in the BsAbs recipients to provide a more comprehensive insight into the nephrotoxicity post-BsAbs therapy. Significantly, due to the limited clinical trial data on each subject, we mainly conclude the related etiologies, mechanisms, and risk factors of nephrotoxicity that occur in T-cell-engaging BsAbs recipients. Nephrotoxicity associated with non-T-cell BsAbs may be associated with adverse nephrotoxicity of related monoclonal antibodies to two specific antigens. The aim of this paper is to provide nephrologists and oncologists with theoretical knowledge to provide better medical management for recipients who receive BsAbs, especially T-cell-engaging BsAbs treatment.© 2024 Wen and Xu.